![UCB SA Website](https://cdn.finchat.io/874491.png)
UCB SA
ENXTBR-UCB
Company Overview
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Name
UCB SA
CEO
Mr. Jean-Christophe Tellier
Website
www.ucb.com
Sector
Pharmaceuticals
Year Founded
1925
Profile
Market Cap
€30.28B
EV
€32.89B
Shares Out
189.72M
Revenue
€5,454M
Employees
9,000
Margins
Gross
67.8%
EBITDA
21.73%
Operating
9%
Pre-Tax
5.24%
Net
4.4%
FCF
12.1%
Returns (5Yr Avg)
ROA
5.55%
ROTA
14.57%
ROE
9.6%
ROCE
9.63%
ROIC
8.06%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
€164
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
€428M
Net Debt
€2,610M
Debt/Equity
0.34
EBIT/Interest
3.09
Growth (CAGR)
Rev 3Yr
-0.38%
Rev 5Yr
3.08%
Rev 10Yr
5.93%
Dil EPS 3Yr
-36.85%
Dil EPS 5Yr
-19.03%
Dil EPS 10Yr
-0.28%
Rev Fwd 2Yr
12.54%
EBITDA Fwd 2Yr
23.35%
EPS Fwd 2Yr
30.62%
EPS LT Growth Est
7.5%
Dividends
Yield
—
Payout
107.67%
DPS
€1.36
DPS Growth 3Yr
2.31%
DPS Growth 5Yr
2.36%
DPS Growth 10Yr
2.72%
DPS Growth Fwd 2Yr
2.94%